A pilot study to investigate whether adding maraviroc to existing therapy has any effect for people with HIV and fatty liver disease
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms HEPMARC
- 08 Oct 2019 Status changed from active, no longer recruiting to recruiting.
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2018 New trial record